Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Targeting thymic stromal lymphopoietin - Novel anti-inflammatory compounds for the treatment and prevention of atopic diseases

FY 2020-21

Summary
The most common inflammatory skin disease worldwide is atopic dermatitis (AD) and up to 17% of Canadians are affected during their lifetime. AD impairs the quality of life as patients suffer from very dry skin, as well as social stigmatism. Additionally, AD often results in development of further allergies such as food allergies, hay fever or allergic asthma. Thus, AD has a significant socioeconomic impact. Because AD is a highly complex, multifactorial disease, its underlying mechanisms are not fully understood. However, over the past years, the keratinocyte-derived cytokine thymic stromal lymphopoietin (TSLP) has been identified as a key player in skin inflammation and a trigger for the development of further allergies. Pharmaceutical companies have developed inhibitors of TSLP, such as tezepelumab, the most advanced drug showing promising results. However, tezepelumab is a protein that must be administered systemically and cannot be applied locally, for example as a cream. Drugs that can be applied locally offer several advantages such as reduced side effects, targeted drug delivery at the site of action, and higher acceptance rates among patients. Moreover, current treatment options for AD are subpar due to treatment-limiting side effects which prevents their continuous use. This interdisciplinary project aims to address both issues by developing blockers of TSLP that can be applied topically. To achieve this, we will first develop potent low molecular weight TSLP inhibitors. These will then be tested for efficacy and tolerability in 2D and 3D cell cultures. The most promising compounds will be tested in animal models of AD. The goal is to develop new topical treatment options for AD, and the prevention of the development of further allergic diseases such as asthma.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449421
Name
Bhagat Vriti
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting thymic stromal lymphopoietin - Novel anti-inflammatory compounds for the treatment and prevention of atopic diseases
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atopic Diseases; Drug Discovery And Development; Inflammatory Skin Diseases; New Anti-Inflammatory Drugs; Topical Drug Delivery; Tslp Inhibitors
Abstract
The most common inflammatory skin disease worldwide is atopic dermatitis (AD) and up to 17% of Canadians are affected during their lifetime. AD impairs the quality of life as patients suffer from very dry skin, as well as social stigmatism. Additionally, AD often results in development of further allergies such as food allergies, hay fever or allergic asthma. Thus, AD has a significant socioeconomic impact. Because AD is a highly complex, multifactorial disease, its underlying mechanisms are not fully understood. However, over the past years, the keratinocyte-derived cytokine thymic stromal lymphopoietin (TSLP) has been identified as a key player in skin inflammation and a trigger for the development of further allergies. Pharmaceutical companies have developed inhibitors of TSLP, such as tezepelumab, the most advanced drug showing promising results. However, tezepelumab is a protein that must be administered systemically and cannot be applied locally, for example as a cream. Drugs that can be applied locally offer several advantages such as reduced side effects, targeted drug delivery at the site of action, and higher acceptance rates among patients. Moreover, current treatment options for AD are subpar due to treatment-limiting side effects which prevents their continuous use. This interdisciplinary project aims to address both issues by developing blockers of TSLP that can be applied topically. To achieve this, we will first develop potent low molecular weight TSLP inhibitors. These will then be tested for efficacy and tolerability in 2D and 3D cell cultures. The most promising compounds will be tested in animal models of AD. The goal is to develop new topical treatment options for AD, and the prevention of the development of further allergic diseases such as asthma.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bhagat, Vriti
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~